Hey you guys
As many of you know in 2005 the FDA warned us (healthcare professionals) about monitoring your cardiac function if you were on Novantrone. Apparently recent indications are that most physicians ARENT following those recommendations. Maybe your doc needs a reminder.....as did I.
1) Patients who are assessed with a cardiac echocardiogram (ultrasound of the heart) and have a baseline LVEF (left ventricular ejection fraction) result below the lower limit of normal should not be treated with mitoxantrone (Novantrone)
2) Patients should be assessed for cardiac abnormalities before receiving each dose of mitoxantrone (Novantrone) through the use of history taking, physical examination, and an EKG.
3) Patients should undergo a reevaluation of cardiac function before receipt of each dose of mitoxantrone.
4) Additional doses of mitoxantrone should not be administered to patients who have experienced either a decrease in LVEF to below the lower limit of normal or a clinically significant reduction in LVEF during mitoxantrone therapy.
5) Patients should undergo yearly cardiac evaluation after stopping mitoxantrone to monitor for late-occurring cardiotoxicity,